Phio Pharmaceuticals Corp.: Form 10-Q/A for the period ended Jun 30, 2017
Filed with the SEC on Mar 26, 2018 and accepted by EDGAR at Mar 26, 2018, 16:38 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-04-01 to 2017-06-30 | $1.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2017-01-01 to 2017-06-30 | $2.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-04-01 to 2017-06-30 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-01-01 to 2017-06-30 | −$9.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 6 months2017-01-01 to 2017-06-30 | −$1.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-04-01 to 2017-06-30 | −$2.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-01-01 to 2017-06-30 | −$8.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-04-01 to 2017-06-30 | −$1.12 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2017-01-01 to 2017-06-30 | −$3.71 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 6 months2017-01-01 to 2017-06-30 | $188.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-06-30 | $7.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-06-30 | $8.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-06-30 | $8.4m | us-gaap:Assets |
| Current liabilities | At period end2017-06-30 | $2.5m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2017-06-30 | $5.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-18-096008. Last ingested by Listed: Nov 12, 2026, 20:44 ET. Listed shows no prices and gives no investment advice.